New drug STLX-2012 tested for safety in healthy people
Knowledge-focused
Not yet recruiting
This early-phase study tests a single dose of the investigational drug STLX-2012 in 32 healthy adults aged 18-55. The main goal is to check for side effects and how the drug moves through the body. No treatment benefit is expected since participants are healthy.
Phase: PHASE1 • Sponsor: Stelexis BioSciences • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:49 UTC